Is systemic lupus erythematosus a new risk factor for atherosclerosis?;Lupus eritematoso sistêmico: Novo fator de risco para aterosclerose?

Arquivos Brasileiros de Cardiologia

Volumn 87, Issue 3, 2006, Pages

  Freire, Beatriz Funayama Alvarenga ^a,b   Da Silva, Rogério Cardoso ^a   Fabro, Alexandre Todorovic ^a   Dos Santos, Daniela Cristina ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b NONE   (Brazil)

Author keywords

Atherosclerosis; Cardiovascular disease; Systemic lupus erythematosus

Indexed keywords

ANTIMALARIAL AGENT; IMMUNOSUPPRESSIVE AGENT; STEROID;

ADULT; ANGINA PECTORIS; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE DURATION; ETHNIC DIFFERENCE; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PREVALENCE; STROKE; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 33750378791     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Fessel WJ. Systemic lupus erythematosus in the community. Arch Int Med 1974;134:1027-35.
2. Dubois EL, Tufanelli DE. Clinical manifestations of systemic lupus erythematosus. Computer analysis of 520 cases. JAMA 1964; 90:377-86.
3. Wallace DJ, Podell T, Weiner J, Klinenberg JR, Forwzesk S, Dubois EL. Systemic lupus erythematosus survival patterns. Experience with 609 patients. JAMA 1981; 245(9):934-8.
4. Urowitz MB, Bookman AAM, Koehler BE, et al. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 1976;60:221-5.
5. Manzi S, Meilahn EN, Rairie, JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with Framinghan study. Am J Epidemiol 1997; 145(5): 408-15.
6. Petri M, Perez-Gutthann S, Spence D, Hochberg MC. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 1992;93:513-9.
7. Helve T. Prevalence and mortality rates of systemic lupus erythematosus and cause of death in SLE patients in Finland. Scand J Rheumatol 1985; 14: 43-6.
8. Abu-Shakra M, Urowitz MB, Gladman DD, Gough J. Mortality studies in systemic lupus erythematosus. Causes of death. J Rheumatol 1995; 22: 1259-64.
9. Dubois EL, Wurzchowiechi M, Cox MB, Wiener DM. Duration and death in systemic lupus erythematosus. JAMA 1974; 227: 1399-402.
10. Aranow C, Ginzler EM. Epidemiology of cardiovascular disease in systemic lupus erythematosus. Lupus 2000;9:166-9.
11. Bulkley BH, Roberts WC. The heart in systemic lupus erythematosus and changes induced in it by corticosteroids therapy: a study of 36 necropsy patients. Am J Med 1975; 58: 243-64.
12. Shome GP, Sakachi M, Yamame K, et al. Ischemic heart disease in systemic lupus erythematosus. A retrospective study of 65 patients treated with prednisone. Japan J Med 1989; 28: 599-603.
13. Freire BFA. Aterosclerose no lupus eritematoso sistêmico. Temas de reumatologia 2001; 2(4): 119-24.
14. Petri M. Detection of coronary artery disease and the role traditional risk factors in the Hopkins Lupus Cohort. Lupus 2000; 9:170-5.
15. Manzi S, Selzer F, Sutton-Tyrrel K, et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum 1999; 42(1): 51-60.
16. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.
17. No authors listed. Report of the expert committee on the diagnosis ond classification of diabetes mellitus. Diabetes care 1997;20(7):1183-97.
18. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertention 2003;42:1206-52.
19. No authors listed. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, avaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001;285(19):2486-97.
20. Fisher LD and Van Belle G. Biostatistics: A methodology for the health sciences. New York: John Wiley & Sons, 1993.
21. Kao AH, Sabatine JM, Manzi S. Update on vascular disease in systemic lupus erythematosus. Curr Opin Rheumatol 2003;15:519-27.
22. Esdaile JM, Abrahamowicz M, Grodizicky T, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001; 44:2331-7.
23. Falaschi F, Ravell A, Martignoni A, et al. Nephrotic-range proteinuria, the major risk factor for early atherosclerosis in juvenile-onset systemic lupus erythematosus. Arthritis Rheum 2000; 43(6):1405-9.
24. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340:115-26.
25. Petri M, Roubenoff R, Dallal GE, et al. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet 1996;348:1120-4
26. Formiga F, Meco JF, Pinto X, et al. Lipid and lipoprotein levels in premenopausal systemic lupus erythematosus patients. Lupus 2001; 10:359-63.
27. Jimenez S, Garcia-Criado MA, Tassies D, et al. Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome. Rheumatology.(Oxford).
28. Roman MJ, Shanker BA, Davis A, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003;349(25):2399-406.
29. Doria A, Shoenfeld Y, Wu R, et al. Risk factors for subclinical atherosclerosis a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 2003; 62:1071-7.
30. Raza K, Thambyrajah J, Townend JN, et al. Suppression of inflammation in primary systemic vasculitis restores vascular endothelial function: lessons for atherosclerotic disease? Circulation 2000; 102:1470-2.
31. Rahman P, Gladman DD, Urowitz MB, et al. The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs. J Rheumatol 1999;26(2):325-30.
32. Vaarala O, Alfthan G, Jauhiainen M, Leirisalo-Repo M, Aho K, Palosuo T. Crossreaction between antibodies to oxidised lipoprotein and cardiolipin in systemic lupus erythematosus. Lancet 1993; 341:923-5
33. Vaarala O, Puurunen M, Mänttäri M, Manninen V, Aho K, Palosuo T. Antibodies to prothrombin imply a risk of myocardial infarction in middle-age men. Thromb Haemost 1996; 75:456-9.
34. Bertolaccini MI, Atsumi T, Khamashta MA, Amengual O, Hughes GR. Autoantibodies to human prothrombin and clinical manifestations in 207 patients with systemic lupus erythematosus. Rheumatol 1999; 25(6):1007-8.
35. Harris EN, Gharavi AE, Boey ML, et al. Antiocardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983; 2:1211-4
36. George J, Harats D, Gilburd B, et al. Immunolocalization of β 2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques. Potential implications for lesions progression. Circulation 1999; 99:2227-30.
37. Hasunuma Y, Matsuura E, Makita Z, Katahira T, Nishi S, Koike T. Involvement of β2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low density lipoprotein uptake by macrophages. Clin Exp Immunol 1997; 107:569-73.
38. George J, Afek A, Gilburd, B et al. Induction of early atherosclerosis in LDL-receptor-deficient mice immunized with β2-glycoprotein I. Circulation 1998; 98:1108-15.
39. Afek A, George J, Shoenfeld Y, et al. Enhancement of atherosclerosis in β2-glycoprotein I-immunized apolipoprotein E-deficient mice. Pathobiology 1999; 67:19-25
40. Cuadrado MJ, Tinahones F, Camps MT, et al. Antiphospholipid, anti-β2-glycoprotein I and anti-oxidized-low-density antibodies in antiphospholipid syndrome. Q J Med 1998; 91:619-26.
41. Reichlin M, Fesmire J, Quintero-Del-Rio AI, et al. Autoantibodies to lipoprotein lipase and dyslipidemia in systemic lupus erythematosus. Arthritis Rheum 2002; 46:2957-63.
42. Desai-Mehta A, Lu L, Ramsey-Goldman R, et al. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production . J Clin Invest 1996; 97:2063-73.
43. Kotowicz K, Dixon GL, Klein NJ, et al. Biological function of CD40 on human endothelial cells: costimulation with CD40 ligand and interleukin-4 selectively induces expression of vascular cell adhesion molecule-1 and P-selectin resulting in preferential adhesion of lymphocytes. Immunology 2000; 100:441-8
44. Lima DS, Sato EI, Lima VC, et al. Brachial endothelial function is impaired in patients with systemic lupus erythematosus. J Rheumatol 2001; 29:292-7.
45. Speidl WS, Graf S, Hornykewycz S, et al. High-sensitivity C-reactive protein in the prediction of coronary events in patients with premature coronary artery disease. Am Heart J 2002; 144:449-55.
46. Tedesco F, Fischetti F, Pausa M, et al. Complement-endothelial cell interactions: pathophysiological implications. Mol Immunol 1999; 36:261-268
47. Torzewski M, Klouche M, Hock J, et al. Immunohistochemical demonstration of enzymatically modified human LDL and its colocalization with the terminal complement complex in the early atherosclerotic lesion. Arterioscler Thromb Vasc Biol 1998; 18:369-78.
48. Mustafa A, Nityanand S, Berglund L, et al. Circulating immune complexes in 50-year-old men as a strong and independent risk factor for myocardial infarction. Circulating 2000; 102:2576-81.